MARKET

ASMB

ASMB

Assembly
NASDAQ

Real-time Quotes | Nasdaq Last Sale

12.75
+0.75
+6.25%
After Hours: 12.75 0 0.00% 16:00 09/17 EDT
OPEN
11.94
PREV CLOSE
12.00
HIGH
13.17
LOW
11.81
VOLUME
402.72K
TURNOVER
--
52 WEEK HIGH
38.42
52 WEEK LOW
10.58
MARKET CAP
327.83M
P/E (TTM)
-3.4797
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of ASMB and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 6 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

ASMB News

  • Investors Who Bought Assembly Biosciences (NASDAQ:ASMB) Shares A Year Ago Are Now Down 67%
  • Simply Wall St..2d ago
  • Stocks That Hit 52-Week Lows On Wednesday
  • Benzinga.09/04 15:39
  • The Daily Biotech Pulse: Puma Leaps, Aerie Borrows, Hepion Back In Nasdaq's Good Books
  • Benzinga.09/04 11:08
  • The Daily Biotech Pulse: EC Nod For Bristol-Myers Squibb, Kyowa Kirin's Parkinson's Add-On Therapy Approved
  • Benzinga.08/28 11:31

More

Industry

Pharmaceuticals
+0.65%
Pharmaceuticals & Medical Research
+0.57%

Hot Stocks

Name
Price
%Change

About ASMB

Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
More

Webull offers Assembly Biosciences Inc (ASMB) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.